secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001193125-23-029211
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical to acquire NuVasive in $3.1B all-stock merger; 0.75 exchange ratio
--------------------------------------------------------------------------------

- Exchange ratio: 0.75 GMED shares per NUVA share; implied price $57.72; equity value $3.1B.
- Combined ownership: GMED shareholders 72%, NUVA shareholders 28% on fully diluted basis.
- Expects mid-30% EBITDA margin in 3 years and ~$170M in identified cost synergies.
- Dan Scavilla to remain CEO; Chris Barry to support integration; board expands to 11 (3 from NuVasive).
- Transaction expected to close mid-2023, subject to shareholder and regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000119312523029211/0001193125-23-029211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000119312523029211/d434853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-029211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer